MSN Laboratories` Generic Trabectedin Receives Approval in the U.S.
(Reuters) -Spanish pharmaceutical group PharmaMar on Thursday said its nine-month net profit slipped 58% to 54.7 million euros ($63.92 million) from a year ago when it booked a hefty gain from a licence payment.
PharmaMar signs a licensing agreement with RPharm to commercialize Yondelis®
According to Luis Mora, Managing Director of PharmaMar’s Oncology Business Unit: “We see STADA’s infrastructure and internal capabilities playing a key role in helping us to maximize the access to this unique drug for as many sarcoma and ovarian cancer patients as possible.”
PharmaMar (MSE:PHM) has announced today a licensing agreement with Onko Ilac San ve Tic A.S. to commercialize the marinederived anticancer drug Yondelis® (trabectedin) in Turkey.
EMA has recommended that the use of Yondelis (trabectedin) in treating ovarian cancer remain unchanged following a review of a study that investigated Yondelis as a third-line treatment in patients with ovarian cancer. However, the study results will be included in the medicine’s product information to provide healthcare professionals with the most up-to-date information on the effects of Yondelis in patients with ovarian cancer.
EMA has recommended that the use of Yondelis (trabectedin) in treating ovarian cancer remain unchanged following a review of a study that investigated Yondelis as a third-line treatment in patients with ovarian cancer. However, the study results will be included in the medicine’s product information to provide healthcare professionals with the most up-to-date information on the effects of Yondelis in patients with ovarian cancer.
Madrid, May 19th, 2020. - PharmaMar (MSE:PHM) and Key Oncologics (Pty) Ltd announced today an exclusive licensing agreement for the importation, use, marketing, sale and distribution of the marine-derived anticancer drug Yondelis® (trabectedin) in South Africa, Namibia and Botswana.
PharmaMar (MSE:PHM) announces that the results of clinical and pre-clinical studies on Yondelis® (trabectedin) and plocabulin (PM184), compounds of a marine origin, have been presented at the International Congress of the Connective Tissue Oncological Society (CTOS). The Congress was held in Tokyo, Japan, from 13th to 16th November.
SINGAPORE and MELBOURNE, Australia, Oct. 14, 2019 /PRNewswire/ -- Independent pharmaceutical company Specialised Therapeutics Asia (STA) has signed a new license deal, enabling it to provide a global advanced sarcoma therapy to patients in Australia, New Zealand and throughout SE Asia.